|
Variable
|
Pelubiprofen (n =77)
|
Celecoxib (n =68)
|
|---|
|
Age (mean ± SD, year)
|
54.3 ± 11.4
|
54.8 ± 10.8
|
|
Female sex, no. (%)
|
69 (89.6)
|
62 (91.2)
|
|
Disease duration (mean ± SD, month)
|
100.2 ± 104.2
|
89.8 ± 88.1
|
|
ACR functional class
| | |
|
Class I, no. (%)
|
25 (32.5)
|
24 (35.3)
|
|
Class II, no. (%)
|
45 (58.4)
|
40 (58.8)
|
|
Class III, no. (%)
|
7 (9.1)
|
4 (5.9)
|
|
Class IV, no. (%)
|
0 (0.0)
|
0 (0.0)
|
|
DMARD use, no. (%)
|
55 (71.4)
|
47 (69.1)
|
|
Prednisolone use, no. (%)
|
54 (70.1)
|
42 (61.8)
|
- ACR, American College of Rheumatology; DMARD, disease-modifying anti-rheumatic drug.
- P values were determined using the Student t-test or the χ2 test.
